Synopsis
Synopsis
0
VMF
0
Canada
DRUG PRODUCT COMPOSITIONS
0
Weekly News Recap #Phispers
1. 4-methyl-n-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
2. Amn 107
3. Amn-107
4. Amn107
5. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, Hydrochloride (1:1)
6. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, Hydrochloride, Hydrate
7. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, Hydrochloride, Hydrate (1:1:2)
8. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, Hydrochloride, Hydrate (1:2:2)
9. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, Hydrochloride, Hydrate (2:2:3)
10. Nilotinib
11. Nilotinib Dihydrochloride Dihydrate
12. Nilotinib Hydrochloride Anhydrous
13. Nilotinib Hydrochloride Dihydrate
14. Nilotinib Hydrochloride Hydrate
15. Nilotinib Hydrochloride Monohydrate
16. Nilotinib Hydrochloride Sesquihydrate
17. Tasigna
1. 923288-95-3
2. Nilotinib Hydrochloride Anhydrous
3. Nilotinib Hcl
4. 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide Hydrochloride
5. Nilotinib (hydrochloride)
6. K37n7byx3x
7. 4-methyl-n-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide;hydrochloride
8. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, Hydrochloride (1:1)
9. Nilotinib (as Hydrochloride)
10. Unii-k37n7byx3x
11. Amn 107 Hydrochloride
12. Amn-107 Hcl
13. Schembl434496
14. Dtxsid60238968
15. Bcp29532
16. Hy-10159b
17. S5205
18. Ccg-270077
19. Nilotinib Hydrochloride [vandf]
20. Bn164657
21. Nilotinib Hydrochloride Monohydrate- Bio-x
22. Cs-0085192
23. Nilotinib Hydrochloride [orange Book]
24. Nilotinib Hydrochloride Anhydrous [who-dd]
25. Q27281888
26. Nilotinib Hcl;amn 107; Amn107; Amn-107; Nilotinib Hydrochloride Anhydrous
27. 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamidehydrochloride
28. 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide Hydrochloride
29. 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide Hydrochloride
Molecular Weight | 566.0 g/mol |
---|---|
Molecular Formula | C28H23ClF3N7O |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 6 |
Exact Mass | 565.1604706 g/mol |
Monoisotopic Mass | 565.1604706 g/mol |
Topological Polar Surface Area | 97.6 Ų |
Heavy Atom Count | 40 |
Formal Charge | 0 |
Complexity | 817 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2022-09-15
Pay. Date : 2022-08-22
DMF Number : 37161
Submission : 2022-07-08
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2016-03-16
Pay. Date : 2016-02-04
DMF Number : 30088
Submission : 2015-12-31
Status : Active
Type : II
Sichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39648
Submission : 2024-03-27
Status : Active
Type : II
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37531
Submission : 2022-09-30
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2020-08-28
Pay. Date : 2020-05-13
DMF Number : 34874
Submission : 2020-07-14
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-08-13
Pay. Date : 2014-03-19
DMF Number : 28102
Submission : 2014-07-15
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2016-07-05
Pay. Date : 2016-05-05
DMF Number : 30098
Submission : 2015-12-09
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30164
Submission : 2015-12-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26497
Submission : 2012-09-28
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25412
Submission : 2011-10-19
Status : Inactive
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Lead Market Dossiers- Under Development
Registration Country : India
Brand Name :
Dosage Form : Oral Solid Dosage Form
Dosage Strength : 50MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Lead Market Dossiers- Under Development
Registration Country : India
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Lead Market Dossiers- Under Development
Registration Country : India
Brand Name :
Dosage Form : Oral Solid Dosage Form
Dosage Strength : 150MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Lead Market Dossiers- Under Development
Registration Country : India
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Lead Market Dossiers- Under Development
Registration Country : India
Brand Name :
Dosage Form : Oral Solid Dosage Form
Dosage Strength : 200MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Lead Market Dossiers- Under Development
Registration Country : India
Regulatory Info :
Registration Country : Iran
Brand Name : Lotigna
Dosage Form : Hard Gelatin Capsule
Dosage Strength : 150MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Brand Name : Lotigna
Dosage Form : Hard Gelatin Capsule
Dosage Strength : 200MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Naprod is a top player in Oncology & Anesthesia FDF through excellent innovation, discovery of new processes & high-quality production.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Capsules
Dosage Strength : 200MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info : Generic
Registration Country : India
Brand Name :
Dosage Form : CAPSULE
Dosage Strength : 150MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : India
Regulatory Info :
Registration Country : USA
Brand Name : NILOTINIB
Dosage Form : CAPSULE;ORAL
Dosage Strength : 150MG
Packaging :
Approval Date :
Application Number : 218544
Regulatory Info :
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : TASIGNA
Dosage Form : CAPSULE;ORAL
Dosage Strength : EQ 150MG BASE
Packaging :
Approval Date : 2010-06-17
Application Number : 22068
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Capsules
Dosage Strength : 200mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Related Excipient Companies
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Oral
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Oral
Dosage Form : Tablet
Grade : Oral
Application : Emulsifying Agents
Excipient Details : HDK N20 Pharma is used as a pharmaceutical emulsifying agent in tablets, capsules, syrups, and solutions.
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Oral
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Oral
Dosage Form : Tablet
Grade : Oral
Brand Name : Titanium dioxide PRETIOX ...
Application : Coating Systems & Additives
Excipient Details : Titanium dioxide Pretiox AV01FG is used as a coloring and coating agent in oral solid dosage forms such as capsules, tablets, granules, and pellets.
Pharmacopoeia Ref : Fami-QS, Kosher, Halal, OHSAS ...
Technical Specs : Ti 59.95% and O 40.05%
Ingredient(s) : Titanium Dioxide
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Capsule
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Capsule
Grade : Oral
Brand Name : Microlose™ M60 P60
Application : Fillers, Diluents & Binders
Excipient Details : Microlose M60 P60 is used as a filler, binder, directly compressible, and co-processed excipient in tablets and capsules.
Pharmacopoeia Ref : In-house
Technical Specs : Lactose Monohydrate – 40%, Microcrystalline cellulose – 60%
Ingredient(s) : Lactose Monohydrate
Dosage Form : Tablet
Grade : Oral
Dosage Form : Injectable / Parenteral
Grade : Parenteral
Brand Name : Lactose Monohydrate
Application : Parenteral
Excipient Details : Lactose monohydrate is used as a diluent in inhalation and lyophilized preparations.
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Oral, Topical
Application : Solubilizers
Excipient Details : Poloxamer 188 is used as a solubilizer, emulsifier, stabilizer in parenteral, OSDs & topical formulations such as creams, gels & lotions.
Pharmacopoeia Ref : ChP/USP/EP
Technical Specs : Oxyethylene unit: 75%-85%, Oxypropylene unit: 25%-30%
Ingredient(s) : Poloxamer 188
Dosage Form : Clinical Supply
Grade : Oral
Application : Empty Capsules
Excipient Details : ACGCAPS™ GC is specially designed for use in clinical trials and comes in the available sizes: AA, A & B.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Gelatin, Unspecified
Dosage Form : Inhalation
Grade : Inhalation
Application : Empty Capsules
Excipient Details : ACGCAPS™ GI / HI is available in gelatin and cellulose (HPMC) material options and is designed for optimal performance with DPI formulations and various inhalation devices.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Gelatin, Unspecified
Dosage Form : HardGel
Grade : Oral
Application : Empty Capsules
Excipient Details : ACGCAPS™ GL / HL is available in gelatin and cellulose (HPMC) material options and can be used for liquids, semi-liquids, hot-melts and combination fills.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Gelatin, Unspecified
Dosage Form : HardGel
Grade : Oral
Application : Empty Capsules
Excipient Details : ACGCAPS™ GR can fulfill immediate release needs and is available in 15 sizes (from # 000 to # 5).
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Gelatin, Unspecified
Dosage Form : Tablet
Grade : Not Available
Brand Name : Magnesium Stearate
Application : Lubricants & Glidants
Excipient Details : Lubricants, Anti-adhesive, Glidant
Dosage Form : Tablet
Grade : Not Available
Application : Emulsifying Agents
Excipient Details : Glidant; Emulsion Stabilizer; Anti-caking Agent.
Dosage Form : Tablet
Grade : Not Available
Brand Name : Kolliphor P188 micro
Application : Direct Compression
Excipient Details : Dissolution enhancer, lubricant & wetting agent, Hydrophilic lubricant, effervescent tablets.
Pharmacopoeia Ref : Ph. Eur., USP-NF: Poloxamer 18...
Technical Specs : Not Available
Ingredient(s) : Microprilled Poloxamer
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
CAS Number : 641571-10-0
Quantity Per Vial :
Sale Unit :
Price :
Details : Creative peptides is specialized in the proce...
Monograph :
Storage :
Code/Batch No : Z10-101-139
Nilotinib Related compound C (25 mg) (3-Amino...
CAS Number : 2458-12-0
Quantity Per Vial : 25
Sale Unit : mg
Price : $730.00
Details : Material Origin- Chemical Synthesis; USMCA- N...
Monograph :
Storage :
Code/Batch No : Catalog #1463457 / F093W0
CAS Number : 923288-90-8
Quantity Per Vial : 350
Sale Unit : mg
Price : $490.00
Details : Material Origin- Chemical Synthesis; USMCA- N...
Monograph :
Storage :
Code/Batch No : Catalog #1463428 / F093T0
Nilotinib Related Compound A (25 mg) (3-(4-Me...
CAS Number : 641571-11-1
Quantity Per Vial : 25
Sale Unit : mg
Price : $730.00
Details : Material Origin- Chemical Synthesis; USMCA- N...
Monograph :
Storage :
Code/Batch No : Catalog #1463439 / F093U0
Nilotinib System Suitability Mixture (10 mg)
CAS Number :
Quantity Per Vial : 10
Sale Unit : mg
Price : $725.00
Details : Material Origin- Chemical Synthesis; USMCA- N...
Monograph :
Storage :
Code/Batch No : Catalog #1463461 / F093X0
ABOUT THIS PAGE
A Nilotinib Hydrochloride Monohydrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nilotinib Hydrochloride Monohydrate, including repackagers and relabelers. The FDA regulates Nilotinib Hydrochloride Monohydrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nilotinib Hydrochloride Monohydrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nilotinib Hydrochloride Monohydrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Nilotinib Hydrochloride Monohydrate supplier is an individual or a company that provides Nilotinib Hydrochloride Monohydrate active pharmaceutical ingredient (API) or Nilotinib Hydrochloride Monohydrate finished formulations upon request. The Nilotinib Hydrochloride Monohydrate suppliers may include Nilotinib Hydrochloride Monohydrate API manufacturers, exporters, distributors and traders.
click here to find a list of Nilotinib Hydrochloride Monohydrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Nilotinib Hydrochloride Monohydrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Nilotinib Hydrochloride Monohydrate active pharmaceutical ingredient (API) in detail. Different forms of Nilotinib Hydrochloride Monohydrate DMFs exist exist since differing nations have different regulations, such as Nilotinib Hydrochloride Monohydrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Nilotinib Hydrochloride Monohydrate DMF submitted to regulatory agencies in the US is known as a USDMF. Nilotinib Hydrochloride Monohydrate USDMF includes data on Nilotinib Hydrochloride Monohydrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nilotinib Hydrochloride Monohydrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Nilotinib Hydrochloride Monohydrate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Nilotinib Hydrochloride Monohydrate Drug Master File in Japan (Nilotinib Hydrochloride Monohydrate JDMF) empowers Nilotinib Hydrochloride Monohydrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Nilotinib Hydrochloride Monohydrate JDMF during the approval evaluation for pharmaceutical products. At the time of Nilotinib Hydrochloride Monohydrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Nilotinib Hydrochloride Monohydrate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Nilotinib Hydrochloride Monohydrate Drug Master File in Korea (Nilotinib Hydrochloride Monohydrate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Nilotinib Hydrochloride Monohydrate. The MFDS reviews the Nilotinib Hydrochloride Monohydrate KDMF as part of the drug registration process and uses the information provided in the Nilotinib Hydrochloride Monohydrate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Nilotinib Hydrochloride Monohydrate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Nilotinib Hydrochloride Monohydrate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Nilotinib Hydrochloride Monohydrate suppliers with KDMF on PharmaCompass.
A Nilotinib Hydrochloride Monohydrate CEP of the European Pharmacopoeia monograph is often referred to as a Nilotinib Hydrochloride Monohydrate Certificate of Suitability (COS). The purpose of a Nilotinib Hydrochloride Monohydrate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Nilotinib Hydrochloride Monohydrate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Nilotinib Hydrochloride Monohydrate to their clients by showing that a Nilotinib Hydrochloride Monohydrate CEP has been issued for it. The manufacturer submits a Nilotinib Hydrochloride Monohydrate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Nilotinib Hydrochloride Monohydrate CEP holder for the record. Additionally, the data presented in the Nilotinib Hydrochloride Monohydrate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Nilotinib Hydrochloride Monohydrate DMF.
A Nilotinib Hydrochloride Monohydrate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Nilotinib Hydrochloride Monohydrate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Nilotinib Hydrochloride Monohydrate suppliers with CEP (COS) on PharmaCompass.
A Nilotinib Hydrochloride Monohydrate written confirmation (Nilotinib Hydrochloride Monohydrate WC) is an official document issued by a regulatory agency to a Nilotinib Hydrochloride Monohydrate manufacturer, verifying that the manufacturing facility of a Nilotinib Hydrochloride Monohydrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Nilotinib Hydrochloride Monohydrate APIs or Nilotinib Hydrochloride Monohydrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Nilotinib Hydrochloride Monohydrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Nilotinib Hydrochloride Monohydrate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nilotinib Hydrochloride Monohydrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Nilotinib Hydrochloride Monohydrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Nilotinib Hydrochloride Monohydrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Nilotinib Hydrochloride Monohydrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nilotinib Hydrochloride Monohydrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Nilotinib Hydrochloride Monohydrate suppliers with NDC on PharmaCompass.
Nilotinib Hydrochloride Monohydrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nilotinib Hydrochloride Monohydrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nilotinib Hydrochloride Monohydrate GMP manufacturer or Nilotinib Hydrochloride Monohydrate GMP API supplier for your needs.
A Nilotinib Hydrochloride Monohydrate CoA (Certificate of Analysis) is a formal document that attests to Nilotinib Hydrochloride Monohydrate's compliance with Nilotinib Hydrochloride Monohydrate specifications and serves as a tool for batch-level quality control.
Nilotinib Hydrochloride Monohydrate CoA mostly includes findings from lab analyses of a specific batch. For each Nilotinib Hydrochloride Monohydrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nilotinib Hydrochloride Monohydrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Nilotinib Hydrochloride Monohydrate EP), Nilotinib Hydrochloride Monohydrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nilotinib Hydrochloride Monohydrate USP).
LOOKING FOR A SUPPLIER?